Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
Body composition imaging expertise you can rely on.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
[Needham, MA] – June 20, 2025 – Perceptive Discovery, a global leader in molecular and functional imaging research, today announced the launch of the FIBRE (Fibrosis Imaging Biomarker Research & Evaluation) Consortium, a bold pre-competitive collaboration with Pfizer, Lantheus, and Lumina Pharmaceuticals. This pioneering initiative aims to revolutionize the treatment of multi-organ fibrotic diseases by advancing cutting-edge imaging biomarkers to accelerate the development of life-changing therapies.
The FIBRE Consortium brings together world-class expertise in drug development and advanced imaging to address a significant and growing unmet medical need. By leveraging Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI), the consortium aims to identify and validate early disease biomarkers, streamlining and optimizing the development of disease-modifying therapies for fibrosis. All studies will be conducted at the Perceptive Discovery London Imaging Center, ensuring the highest standards in data acquisition and imaging analysis.
Initial studies will focus on Metabolic Dysfunction-Associated Steatohepatitis (MASH), with potential future expansion into other fibrotic conditions. Imaging research will evaluate tracers targeting Fibroblast Activation Protein (FAP) and Collagen Type I in both patients and healthy volunteers to detect biomarkers of early disease progression.
“Fibrotic diseases are progressive and debilitating, with a pressing need for therapies that can truly modify the course of the disease,” said Eugenii A. Rabiner, EVP and Global Head of Translational Applications at Perceptive Discovery. “Molecular and functional imaging biomarkers offer a powerful way to transform early-phase drug development—enabling more precise decisions, reducing trial size and cost, and increasing the likelihood of success in bringing new therapies to the patients who need them most.”
The FIBRE Consortium also represents a major step toward standardizing care for fibrotic diseases by promoting cross-sector collaboration and shared data. Inspired by the success of MIND MAPS (Molecular Imaging in Neurodegeneration – Mitochondria, Associated Proteins, and Synapses), a previous collaboration between Perceptive Discovery, Pfizer and other leading pharma / academic collaborators, FIBRE is designed to expand cross-disease biomarker research and attract new biotech and pharmaceutical partners. Each new member will have the opportunity to lead disease-specific cohort studies and contribute to a growing foundation of knowledge shaping the future of fibrosis treatment.
Lantheus, the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, will supply the precursor to its PET imaging agent targeting FAP (LNTH-1363S), which will be radiolabeled with 18F by Perceptive for clinical research use in the FIBRE consortium studies. FAP is a membrane-bound dipeptidyl peptidase that is selectively expressed in activated fibroblasts during the development and progression of fibrosis.
Lumina Pharmaceuticals, a clinical-stage pharmaceutical company, will contribute [⁶⁸Ga]CBP8, a tracer targeting Collagen Type I, the dominant collagen type produced during pathological fibrosis. [⁶⁸Ga]CBP8 PET imaging has been shown to quantify pulmonary fibrosis in patients and measure collagen changes over time or in response to therapeutic intervention.
For more information about the FIBRE Consortium or to explore partnership opportunities, please contact us at hello@perceptive.com or visit www.fibreconsortium.com
About Perceptive Discovery
Perceptive Discovery is a leading imaging research organization focused on developing and applying molecular and functional imaging technologies to accelerate drug discovery and development. With cutting-edge facilities and a global network of collaborators, Perceptive empowers innovation in biomarker-driven science. For more information, visit www.perceptive.com
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Switzerland, and Sweden, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit www.lantheus.com
About Lumina Pharmaceuticals
Lumina Pharmaceuticals is a clinical-stage radiopharmaceutical company distinguished by its innovative peptide technology, the culmination of over ten years of research. This technology targets novel biomarkers that are abundantly present in various disease states yet largely absent in healthy humans. Lumina’s lead asset is a potential pan-cancer theranostic, targeting fibrin within the extracellular matrix of solid tumors. Led by industry-leading scientists and experienced executives, Lumina is committed to accelerating the advancement of its diagnostic and therapeutic radiopharmaceutical pipeline. For more information, visit www.luminapharma.com
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
"*" indicates required fields
Δ
